ArticlePCN reports : psychiatry and clinical neurosciences2025
Successful treatment of delusional disorder, somatic type by escitalopram: A case report and literature review.
Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Late-Onset Oral Cenesthopathy With Dopaminergic Dysfunction: Therapeutic Response to Pramipexole in a Case With Suspected Prodromal Lewy Body Disease.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2025Article
- Successful treatment of delusional disorder, somatic type by escitalopram: A case report and literature review.PCN reports : psychiatry and clinical neurosciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Delusional disorder, somatic type (DDST) is characterized by the presence of persistent delusions related to having a physical illness or bodily dysfunction, despite contradictory medical evidence. Antipsychotics like pimozide have shown efficacy in the treatment of DDST, and several case reports suggest that antidepressants may also be effective for this disorder. We are the first to report the effectiveness of escitalopram, which is a most selective and potent serotonin reuptake inhibitor, in a patient with DDST. Case Presentation: The case was a 62-year-old woman with DDST, presenting with oral somatic delusions. Escitalopram treatment (10 mg/day, increased to 20 mg/day) led to significant symptom improvement, and the symptoms of DDST had nearly resolved ∼5 weeks after the initiation of escitalopram. Single-photon emission computed tomography imaging during DDST symptoms showed reduced regional cerebral blood flow (rCBF) in the cerebral cortex, particularly in the temporal and parietal lobes, with follow-up imaging after 9 weeks of escitalopram treatment demonstrating rCBF improvement correlating with clinical recovery. Conclusion: This case suggests that escitalopram was effective in treating DDST, providing further support for the involvement of serotonergic dysfunction in the pathophysiology of DDST. The improvement in rCBF following treatment suggests that DDST may be associated with reduced rCBF in the temporal and parietal lobes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.